RICHELDI, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.849
AS - Asia 8.570
EU - Europa 8.490
SA - Sud America 1.201
AF - Africa 196
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 21
Totale 39.360
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.558
GB - Regno Unito 2.774
SG - Singapore 2.643
CN - Cina 2.339
IT - Italia 1.889
HK - Hong Kong 1.009
BR - Brasile 916
VN - Vietnam 862
SE - Svezia 798
FI - Finlandia 600
DE - Germania 599
UA - Ucraina 504
FR - Francia 385
RU - Federazione Russa 349
TR - Turchia 332
BD - Bangladesh 310
KR - Corea 237
IN - India 217
BG - Bulgaria 172
CA - Canada 163
ID - Indonesia 122
NL - Olanda 101
AR - Argentina 87
MX - Messico 78
IQ - Iraq 75
ZA - Sudafrica 69
PK - Pakistan 63
JP - Giappone 55
EC - Ecuador 48
IE - Irlanda 43
ES - Italia 38
PL - Polonia 38
AE - Emirati Arabi Uniti 35
BE - Belgio 34
CO - Colombia 32
AT - Austria 30
UZ - Uzbekistan 30
CL - Cile 27
MY - Malesia 27
VE - Venezuela 25
IR - Iran 24
AU - Australia 22
PY - Paraguay 22
MA - Marocco 21
PE - Perù 21
NG - Nigeria 20
PH - Filippine 20
SA - Arabia Saudita 20
CH - Svizzera 18
TW - Taiwan 17
AL - Albania 16
AZ - Azerbaigian 16
JO - Giordania 16
TH - Thailandia 15
TN - Tunisia 15
CZ - Repubblica Ceca 14
DZ - Algeria 14
EG - Egitto 13
EU - Europa 13
KE - Kenya 13
LT - Lituania 11
NP - Nepal 11
OM - Oman 11
IL - Israele 10
UY - Uruguay 10
BO - Bolivia 9
DK - Danimarca 8
HN - Honduras 8
JM - Giamaica 8
SN - Senegal 8
LB - Libano 7
PT - Portogallo 7
BH - Bahrain 6
CR - Costa Rica 6
ET - Etiopia 6
GR - Grecia 6
LV - Lettonia 6
PS - Palestinian Territory 6
RO - Romania 6
RS - Serbia 6
AM - Armenia 5
DO - Repubblica Dominicana 5
EE - Estonia 5
FJ - Figi 5
HR - Croazia 5
KG - Kirghizistan 5
MD - Moldavia 5
NO - Norvegia 5
PA - Panama 5
SK - Slovacchia (Repubblica Slovacca) 5
GT - Guatemala 4
NZ - Nuova Zelanda 4
SY - Repubblica araba siriana 4
XK - ???statistics.table.value.countryCode.XK??? 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BY - Bielorussia 3
GE - Georgia 3
KZ - Kazakistan 3
TT - Trinidad e Tobago 3
AO - Angola 2
Totale 39.302
Salva come PNG Salva come JPEG
Città #
Fairfield 2.178
Southend 2.014
Ashburn 1.884
Santa Clara 1.702
Singapore 1.695
Woodbridge 1.472
Houston 1.147
Hong Kong 978
Jacksonville 963
Chandler 921
Seattle 822
Hefei 804
Dearborn 752
Wilmington 725
Ann Arbor 696
Cambridge 692
San Jose 618
Nyköping 452
Beijing 449
Helsinki 426
London 410
Chicago 316
Los Angeles 310
Council Bluffs 301
The Dalles 270
Ho Chi Minh City 252
New York 240
Hanoi 216
Seoul 198
San Diego 195
Modena 192
Milan 176
Princeton 172
Sofia 165
Eugene 158
Lauterbourg 140
Salt Lake City 137
Buffalo 130
Izmir 125
Shanghai 91
Dallas 86
Moscow 83
Rome 81
Jakarta 73
Naples 72
Phoenix 68
São Paulo 66
Columbus 64
Des Moines 64
Tampa 62
Frankfurt am Main 53
Palermo 53
Redwood City 49
Bremen 46
Da Nang 43
Elk Grove Village 43
Haiphong 43
Orem 43
Montreal 42
Dublin 40
Atlanta 36
Boardman 35
Guangzhou 35
Tokyo 34
Toronto 34
Brussels 32
Chennai 32
Sterling 32
Turin 32
Florence 31
Norwalk 29
San Francisco 29
Tashkent 29
Bari 28
Bologna 28
Jersey City 28
Warsaw 28
Miano 27
Mumbai 27
Dong Ket 26
Lahore 25
Brooklyn 23
Detroit 23
Munich 23
Philadelphia 23
Rio de Janeiro 23
Baghdad 22
Boston 22
Kunming 22
Denver 21
Lancaster 21
Mexico City 21
Miami 21
Amsterdam 20
Kent 20
Belo Horizonte 19
Changsha 19
Falls Church 19
San Mateo 19
Long Branch 18
Totale 27.794
Salva come PNG Salva come JPEG
Nome #
Malattie infiltrative diffuse del polmone 1.210
Multidrug-resistant tuberculosis outbreak in an Italian prison: Tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays 802
Non-steroid agents for idiopathic pulmonary fibrosis 462
Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study 451
Clinical use of Levofloxacin in the long-term treatment of drug resistant tuberculosis. 450
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis. 440
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 420
T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure 407
Performance of tests for latent tuberculosis in different groups of immunocompromised patients 403
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias 385
Atypical lipomatous tumour (lipoma-like well-differentiated liposarcoma) arising in a pulmonary hamartoma and clinically presenting with pneumothorax 379
T-cell-based diagnosis of neonatal multidrug-resistant latent tuberculosis infection. 361
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 361
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments 358
MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients 356
Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. 355
An Official ATS/ERS/JRS/ALAT Statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management 354
Aortic pulse wave velocity measurement in systemic sclerosis patients. 342
A culture-proven case of community-acquired Legionella pneumonia apparently classified as nosocomial: diagnostic and public health implications 333
Emerging drugs for idiopathic pulmonary fibrosis. 326
Comparison of the tubercolin skin test and the ellispot blood test for the diagnosis of latent tuberculosis infection in pre-transplant dialysis patients 326
Use of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Case Study 323
Room size is the major determinant for tuberculin conversion in health care workers exposed to a multidrug-resistant tuberculosis patient 322
Prior tuberculin skin testing does not boost QuantiFERON-TB results in paediatric contacts 320
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis 320
Role Of The QFT-IT Assay For The Diagnosis Of Latent Tuberculosis Infection Among Adult Immigrants 320
Management of idiopathic pulmonary fibrosis. 314
Efficacy of hormonal suppression in a patient with chyluria due to lymphangioleiomyomatosis 308
Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. 307
Rifabutin for treating pulmonary tuberculosis. 306
Lung fibrosis, bone marrow fibrosis and liver cirrhosis: A Short Telomere Syndrome or a casual association? 301
Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections 300
Home Oxygen Saturation Monitoring And Quality Of Life Evaluation In Patients With Idiopathic Pulmonary Fibrosis: Preliminary Results From A Prospective Multicenter Trial 299
Acute exacerbations of chronic obstructive pulmonary disease: are antibiotics needed? 296
Early diagnosis of subclinical multi drug-resistant tuberculosis 295
Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis 295
Prevalence Of Subclinical Liver Fibrosis Among Patients With Idiopathic Pulmonary Fibrosis 294
Novel drug targets for idiopathic pulmonary fibrosis 292
Pulmonary fibrosis and the many faces of UIP 292
Amyotrophic lateral sclerosis and sarcoidosis: a difficult differential diagnosis. 292
An update on the diagnosis of tuberculosis infection 291
Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection 291
A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM) 291
Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy 288
Macrolides in the treatment of asthma and cystic fibrosis 285
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis 285
Management of Idiopathic Pulmonary Fibrosis 285
HRCT Patterns Of Usual Interstitial Pneumonia In Rheumatoid Lung 285
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. 284
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial 283
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report 282
Sarcoidosis: challenging diagnostic aspects of an old disease. 281
Quantiferon-TB Gold In-Tube Tests In Hospital Health Care Workers: A Five Years Experience 277
Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials 275
A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis 274
Performance of commerical blood tests for the diagnosis of latent tuberculosis infection in children and adolescents 273
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis 271
Prevalence and prognosis of unclassifiable interstitial lung disease 266
Environmental triggers and susceptibility factors in idiopathic granulomatous diseases. 264
Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TB assay 263
Smoking-related interstitial lung disease 259
Blood tests for diagnosis of tuberculosis - Reply 255
Use of a T-cell interferon-γ release assay for the diagnosis of tuberculous pleurisy 254
Mycobacterium tuberculosis induces CCL18 expression in human macrophages 249
RHEUMATOID ARTHRITIS RELATED INTERSTITIAL LUNG DISEASE. RADIOLOGICAL PATTERNS AND CORRELATIONS WITH CLINICAL, SEROLOGICAL AND DEMOGRAPHIC FEATURES OF DISEASE 247
Unexpected identification of bilateral masses in an asymptomatic heavy smoker. 246
The big clinical trials in idiopathic pulmonary fibrosis. 244
Identification Of Potential Candidate Biomarkers In Lymphangioleiomyomatosis Using ITRAQ Proteomic Technology 243
Inappropriatezza prescrittiva dell'ossigenoterapia domiciliare a lungo termine 242
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. 241
Repeated Quantiferon-TB Gold In-Tube Tests In Routine Clinical Practice: A Five Years Experience 241
Validation of a Method for Automatic Detection of Lung Sounds in Fibrotic Interstitial Lung Disease 239
Macrolides for chronic asthma. 235
Levels Of Fibulin-1 In The Lung And Serum Are Increased In Fibrotic Interstitial Lung Disease 235
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis 234
Challenges in idiopathic interstitial lung disease 232
L'infezione tubercolare nel bambino: il contributo dei nuovi test immunologici 230
The complex interrelationships between chronic lung and liver disease: a review. 230
Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis 229
Tuberculosis infection in foreign-born children: a screening survey based on skin and blood testing. 227
Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. 226
MOLECULAR DIAGNOSIS OF TUBERCULOSIS 226
ANTIBODY REPERTOIRE AGAINST THE A60 ANTIGEN COMPLEX DURING THE COURSE OF PULMONARY TUBERCULOSIS 225
Immunomodulatory agents for idiopathic pulmonary fibrosis. 224
Tubercolosi 224
Co-trimoxazole effect on human alveolar macrophages of AIDS patients 224
Role of the quantiferon-TB test in ruling out pleural tuberculosis: a multi-centre study. 223
HLA-DPB1 Glutamate 69: a genetic marker of beryllium disease 219
Analysis of sputum in COPD 216
Immunogenetic basis of environmental lung disease: lessons from the berylliosis model 214
Interaction of genetic and exposure factors in the prevalence of berylliosis 210
The role of biomarkers in low respiratory tract infections. 209
Genetic testing in diffuse parenchymal lung disease 208
Interferon gamma assays for tuberculosis 207
First report of the Italian register for diffuse infiltrative lung disorders (RIPID) 205
Use of commercial interferon-gamma assays in immunocompromised patients for tuberculosis diagnosis 205
Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis 204
New tools for a better diagnosis of latent tuberculosis infection 203
End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosis. 203
Tuberculosis diagnostic tests: Sensitivity, specificity, and comparing apples with apples 202
Totale 29.760
Salva come PNG Salva come JPEG
Categoria #
all - tutte 145.404
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 145.404
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021199 0 0 0 0 0 0 0 0 0 0 0 199
2021/20222.903 86 488 275 221 59 87 200 108 293 208 525 353
2022/20232.694 324 274 169 241 317 402 47 292 331 81 116 100
2023/20242.023 62 129 124 173 372 244 245 244 67 47 128 188
2024/20255.889 212 90 84 417 1.236 847 389 367 631 357 585 674
2025/202612.051 676 489 1.084 1.283 1.747 1.035 1.538 649 1.153 964 883 550
Totale 39.560